Lantheus, headquartered inBillerica, Massachusetts, is a company in theradiopharmaceuticals business. It has strategic partnerships withBayer,Novartis,Regeneron as well asGE Healthcare andSiemens Healthineers.[1][2]
Lantheus Holding, which became a NASDAQ company in 2015, is the parent company of Lantheus Medical Imaging, Inc.[3] (formerlyBMS Medical Imaging), Progenics Pharmaceuticals (acquired 2020),[4][5] Inc. and EXINI Diagnostics AB (est. 1999, acquired 2020).[6] Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden.[7][8][9]
Brian Markison has served as the company's CEO since March 1, 2024, following the retirement of Mary Anne Heino, who had led Lantheus for the preceding decade.[10]
develops, manufactures, and distributes diagnostic imaging products. The Company offers imaging agents that assist in the diagnosis of heart, vascular, and other diseases using nuclear imaging, echocardiography, and magnetic resonance imaging (MRI) technologies. Lantheus Medical Imaging markets its products worldwide.
...established in 1999 to commercialize AI methods for automated analysis of diagnostic images developed by a research group at Lund University. As a certified medical device manufacturer, EXINI has developed automated analysis platforms for cardiac, brain and bone scans. The company has always been innovative, developing web-based systems in the early 2000s. EXINIs most widely distributed platform is used to calculate the automated Bone Scan Index, which quantifies the bone tumor burden in patients with metastatic prostate cancer.